Low risk of nosocomial severe acute respiratory syndrome-coronavirus-2 infection in patients with liver disease admitted to a hepatology unit at an academic hospital: A single-center experience.
Hepatocellular carcinoma
Immunoglobulin G
Immunoglobulin M
Immunosuppression
Liver cirrhosis
Liver transplantation
Nasopharyngeal swab
Nosocomial infection
Reverse transcriptase polymerase chain reaction
SARS-CoV-2 infection
Vaccination
Journal
Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology
ISSN: 0975-0711
Titre abrégé: Indian J Gastroenterol
Pays: India
ID NLM: 8409436
Informations de publication
Date de publication:
06 2022
06 2022
Historique:
received:
01
06
2021
accepted:
13
01
2022
pubmed:
30
6
2022
medline:
17
8
2022
entrez:
29
6
2022
Statut:
ppublish
Résumé
Patients with liver disease may be at increased risk of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infection due to immune dysfunction. However, the risk of nosocomial SARS-CoV-2 infection in these patients remains unknown. This study aimed to determine whether patients with liver disease are at an increased risk of nosocomial transmission of SARS-CoV-2 infection upon admission to the hospital for diagnostic or therapeutic procedures. The study prospectively enrolled 143 patients who were admitted at least once to the hepatology unit at our hospital; 95 patients (66%) were admitted at least twice during the study period. History of past symptomatic SARS-CoV-2 exposure was assessed on the day before hospital admission via an interview. Patients were evaluated for active SARS-CoV-2 infection via real-time reverse transcription-polymerase chain reaction (RT-PCR) performed on nasopharyngeal swabs and tests for serum anti-SARS-CoV-2 immunoglobulin M (IgM) and immunoglobulin G (IgG) antibodies. None of the patients enrolled tested positive for SARS-CoV-2 infection by RT-PCR at the first or the second clinical evaluation. One patient who had previously received a liver transplant and who had a history of symptomatic SARS-CoV-2 infection that occurred 4 months before hospital admission tested positive for anti-SARS-CoV-2 IgG but not IgM antibodies at each of the two hospital admissions. The results of our study suggest that patients with liver disease are at no increased risk of nosocomial SARS-CoV-2 infection. These data support the policy of maintaining clinical hospital checks that will be necessary until or possibly even after the completion of the current SARS-CoV-2 vaccination campaign.
Sections du résumé
BACKGROUND
Patients with liver disease may be at increased risk of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infection due to immune dysfunction. However, the risk of nosocomial SARS-CoV-2 infection in these patients remains unknown. This study aimed to determine whether patients with liver disease are at an increased risk of nosocomial transmission of SARS-CoV-2 infection upon admission to the hospital for diagnostic or therapeutic procedures.
METHODS
The study prospectively enrolled 143 patients who were admitted at least once to the hepatology unit at our hospital; 95 patients (66%) were admitted at least twice during the study period. History of past symptomatic SARS-CoV-2 exposure was assessed on the day before hospital admission via an interview. Patients were evaluated for active SARS-CoV-2 infection via real-time reverse transcription-polymerase chain reaction (RT-PCR) performed on nasopharyngeal swabs and tests for serum anti-SARS-CoV-2 immunoglobulin M (IgM) and immunoglobulin G (IgG) antibodies.
RESULTS
None of the patients enrolled tested positive for SARS-CoV-2 infection by RT-PCR at the first or the second clinical evaluation. One patient who had previously received a liver transplant and who had a history of symptomatic SARS-CoV-2 infection that occurred 4 months before hospital admission tested positive for anti-SARS-CoV-2 IgG but not IgM antibodies at each of the two hospital admissions.
CONCLUSIONS
The results of our study suggest that patients with liver disease are at no increased risk of nosocomial SARS-CoV-2 infection. These data support the policy of maintaining clinical hospital checks that will be necessary until or possibly even after the completion of the current SARS-CoV-2 vaccination campaign.
Identifiants
pubmed: 35768749
doi: 10.1007/s12664-022-01241-8
pii: 10.1007/s12664-022-01241-8
pmc: PMC9244468
doi:
Substances chimiques
Antibodies, Viral
0
COVID-19 Vaccines
0
Immunoglobulin G
0
Immunoglobulin M
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
292-299Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2022. The Author(s).
Références
Respir Investig. 2021 May;59(3):356-359
pubmed: 33579647
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
J Hepatol. 2014 Dec;61(6):1385-96
pubmed: 25135860
Environ Int. 2021 Feb;147:106326
pubmed: 33340987
JHEP Rep. 2020 Oct;2(5):100169
pubmed: 32835190
Gut. 2021 Oct;70(10):1914-1924
pubmed: 34281984
Infect Dis (Lond). 2021 Jun;53(6):460-468
pubmed: 33689558
Am J Transplant. 2021 Jul;21(7):2509-2521
pubmed: 33278850
Hepatol Res. 2020 Oct;50(10):1196-1200
pubmed: 32729953
J Hepatol. 2021 Jan;74(1):148-155
pubmed: 32750442
J Hepatol. 2020 Nov;73(5):1063-1071
pubmed: 32526252
Clin Gastroenterol Hepatol. 2020 Aug;18(9):2131-2133.e1
pubmed: 32334081
Front Immunol. 2021 Sep 03;12:705441
pubmed: 34539635
J Clin Med. 2021 Sep 05;10(17):
pubmed: 34501463
JHEP Rep. 2020 Jun;2(3):100113
pubmed: 32289115
J Hosp Infect. 2020 Oct;106(2):376-384
pubmed: 32702463
Clin Chem. 2020 Apr 1;66(4):549-555
pubmed: 32031583
Emerg Microbes Infect. 2020 Dec;9(1):747-756
pubmed: 32196430
J Hepatol. 2021 Jan;74(1):31-36
pubmed: 32777322
Int J Clin Pract. 2021 Apr;75(4):e13868
pubmed: 33244856